Compare BridgeBio Pharma Inc (BBIO) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Meta Platforms Inc — how do they compare? BridgeBio Pharma Inc trades at $84.71 (market cap $16.46B), while Meta Platforms Inc trades at $663 (market cap $1.68T). The key difference: Meta Platforms Inc is far larger — about 102.1× BridgeBio Pharma Inc's market cap, and Meta Platforms Inc pays a 0.32% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | META | |
|---|---|---|
Market Cap | $16.46B | $1.68T |
Sector | Health | Media |
52-Week High | $90.17 | $790.00 |
52-Week Low | $44.81 | $525.72 |
Enterprise Value | $18.02B | $1.68T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Meta Platforms (META) trades at $656.73, down 1.86% on the day, but maintains strong technical momentum with a bullish moving average signal and key resistance at $663. Fundamentally, the company demonstrates robust profitability with 32.84% net income margin and consistent earnings beats, including Q1 2026 EPS of $10.44 versus $6.70 expected. Recent AI developments, including the Muse Spark launch on April 10, 2026, highlight growth initiatives.
The outlook remains positive with 79% analyst buy ratings and a $815.44 consensus price target suggesting 24% upside. Key risks include ongoing litigation, particularly the Massachusetts youth addiction lawsuit ruled on April 10, 2026, and elevated capital expenditures. Revenue growth trajectory and AI monetization present significant opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
